Piclamilast (RP 73401) is a selective PDE4 inhibitor with IC50 of 1 nM at PDE4 from human neutrophils. Inhibition of PDE4 blocks hydrolysis of cAMP thereby increasing levels of cAMP within cells. cAMP suppresses the activity of immune and inflammatory cells. Piclamilast also inhibits LTB4 synthesis in human neutrophils with IC50 of 2 nM. PDE4 inhibitor Piclamilast (RP 73401) displays >19,000-fold selectivity over other PDE isoenzymes. It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. Piclamilast pre-treatment significantly inhibited the changes in 23 genes via mechanisms involving AP-1 activation and c-Jun phosphorylation at Ser63.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Piclamilast inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H(2)O(2) via mechanisms involving AP-1 activation.
Mata M, et al. Free Radic Res. 2012 May;46(5):690-9. PMID: 22360706.
|Related PDE Products|
Vesnarinone is a cardiotonic agent, mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity.
Roflumilast N-oxide is a phosphodiesterase 4 inhibitor.
CP671305 is a potent and selective, orally active inhibitor of phosphodiesterase-4-D with high activities.
ITI-214 phosphate is an orally active, potent and selective inhibitors of PDE1, exhibits potent PDE1 inhibitory activity (Ki = 58 pM).
IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.